Vascular Therapies appoints John McDermott as chief executive officer

611

Vascular Therapies, a biotechnology company focused on improving outcomes for patients with advanced kidney disease, today announced the appointment of John McDermott as the company’s chief executive officer.

Bob Croce, chairman of the Board of Directors of Vascular Therapies, Inc. comments, “We are very pleased to welcome John as our chief executive officer. John has nearly 30 years of experience in the vascular industry and has led the development and successful commercialisation of multiple ground-breaking new technologies. Sriram Iyer, founder of Vascular Therapies, has done an excellent job leading the company since inception and will continue as its chief scientific officer.”

John McDermott said, “I am honoured to be named as chief executive officer of Vascular Therapies. The company is developing a promising new local vascular drug-delivery technology intended to improve outcomes for patients with advanced kidney disease and I look forward to working with the team at Vascular Therapies and collaborating with physicians to provide this important new therapy to patients worldwide.”

McDermott brings to Vascular therapies nearly 30 years of executive leadership experience in vascular technologies. McDermott’s recent roles include being CEO of Endologix, a developer of aortic stent grafts. Prior to Endologix, McDermott was the president of Bard Peripheral Vascular, a division of C.R. Bard (now owned by Beckton Dickenson). Before Bard Peripheral Vascular, McDermott was the chief operating officer at IMPRA, a developer and manufacturer of vascular grafts.

(Visited 344 times, 3 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here